Orthopediatrics (NASDAQ:KIDS) Lowered to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Orthopediatrics (NASDAQ:KIDS) from a buy rating to a hold rating in a research note released on Saturday morning, Zacks.com reports.

According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “

A number of other brokerages have also commented on KIDS. ValuEngine lowered shares of Orthopediatrics from a buy rating to a hold rating in a research note on Thursday, August 1st. Piper Jaffray Companies boosted their price target on shares of Orthopediatrics from $40.00 to $44.00 and gave the company an overweight rating in a research note on Friday. Finally, BidaskClub lowered shares of Orthopediatrics from a buy rating to a hold rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of Buy and an average price target of $44.40.

Shares of NASDAQ KIDS traded up $1.58 during midday trading on Friday, reaching $37.50. The stock had a trading volume of 125,300 shares, compared to its average volume of 74,879. The firm has a market cap of $560.98 million, a price-to-earnings ratio of -39.06 and a beta of 0.23. The company’s 50 day moving average price is $36.29 and its 200 day moving average price is $36.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.75 and a current ratio of 2.53. Orthopediatrics has a twelve month low of $25.11 and a twelve month high of $47.82.

Orthopediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). The business had revenue of $20.74 million for the quarter, compared to the consensus estimate of $19.87 million. Orthopediatrics had a negative net margin of 15.77% and a negative return on equity of 12.92%. The business’s revenue for the quarter was up 31.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.15) EPS. Equities analysts forecast that Orthopediatrics will post -0.82 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of KIDS. Roubaix Capital LLC bought a new stake in shares of Orthopediatrics in the 2nd quarter worth $3,497,000. Aperio Group LLC bought a new stake in shares of Orthopediatrics in the 2nd quarter worth $39,000. Swiss National Bank bought a new stake in shares of Orthopediatrics in the 2nd quarter worth $640,000. Conestoga Capital Advisors LLC grew its stake in shares of Orthopediatrics by 4.4% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 10,395 shares of the company’s stock worth $405,000 after acquiring an additional 440 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Orthopediatrics by 7.2% in the 2nd quarter. Wells Fargo & Company MN now owns 199,364 shares of the company’s stock worth $7,775,000 after acquiring an additional 13,427 shares in the last quarter. Hedge funds and other institutional investors own 49.01% of the company’s stock.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Further Reading: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Anticipate RPT Realty  to Post $0.27 Earnings Per Share
Zacks: Analysts Anticipate RPT Realty to Post $0.27 Earnings Per Share
Shore Capital Reiterates Buy Rating for SSP Group
Shore Capital Reiterates Buy Rating for SSP Group
Britvic’s  “Hold” Rating Reaffirmed at Liberum Capital
Britvic’s “Hold” Rating Reaffirmed at Liberum Capital
British Land’s  “Neutral” Rating Reiterated at JPMorgan Chase & Co.
British Land’s “Neutral” Rating Reiterated at JPMorgan Chase & Co.
Brokerages Anticipate Unum Group  Will Post Quarterly Sales of $3.02 Billion
Brokerages Anticipate Unum Group Will Post Quarterly Sales of $3.02 Billion
Arrow Global Group  Earns Buy Rating from Shore Capital
Arrow Global Group Earns Buy Rating from Shore Capital


© 2006-2019 Ticker Report